Opiranserin - Vivozon
Alternative Names: VVZ-000149; VVZ-149Latest Information Update: 15 Mar 2023
At a glance
- Originator Vivozon
- Class Benzamides; Non-opioid analgesics; Pyrans; Small molecules
- Mechanism of Action Glycine plasma membrane transport protein inhibitors; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Postoperative pain
- Phase II Fibromyalgia; Myofascial pain
- Discontinued Neuropathic pain; Pain; Pruritus
Most Recent Events
- 14 Mar 2023 Phase-II clinical trials in Fibromyalgia in South Korea (Topical, Gel) (Vivozon pipeline, March 2023)
- 14 Mar 2023 Discontinued - Phase-I for Neuropathic pain (In the elderly, In adults) in USA (IV) before March 2023 (Vivizon pipeline, March 2023)
- 14 Mar 2023 Discontinued - Preclinical for Pain in USA (PO) before March 2023 (Vivizon pipeline, March 2023)